Algeta appoints Dr. Gillies O'Bryan-Tear as Chief Medical Officer
Algeta ASA announces it has appointed Dr. Gillies O'Bryan-Tear as Chief Medical Officer.
Dr. O'Bryan-Tear has more than 20 years' pharmaceutical industry experience in senior roles managing and advising on the clinical development and registration of new drugs and vaccines. He has extensive development and clinical knowledge in oncology and has developed and successfully launched major oncology products. He has worked both as an independent consultant to and in-house for a number of leading biotechnology and pharmaceutical companies. He is the former Vice President of Global Clinical R&D at GlaxoSmithKline Biologicals, spent two years as Interim Medical Director for Genzyme UK, and was previously medical director in the UK and Northern Europe for Bristol-Myers Squibb.
Dr. O'Bryan-Tear has been Acting CMO for Algeta since March 2009 and has been a consultant to the Company on the clinical development of Alpharadin since 2004. Alpharadin (radium-223) is a novel alpha-pharmaceutical and Algeta's lead cancer therapeutic in a global phase III clinical trial (ALSYMPCA) designed to confirm its efficacy and safety as a targeted treatment for bone metastases in patients with advanced, hormone-refractory prostate cancer.
Topics
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.